Navigation Links
CRESTOR Demonstrates Dramatic CV Risk Reduction in a Large Statin Outcomes Study
Date:11/9/2008

NEW ORLEANS, Nov. 9 /PRNewswire-FirstCall/ -- New data from the JUPITER study demonstrated that CRESTOR(R) (rosuvastatin calcium) 20 mg significantly reduced major cardiovascular (CV) events (defined in this study as the combined risk of myocardial infarction, stroke, arterial revascularization, hospitalization for unstable angina, or death from CV causes) by a dramatic 44% compared to placebo (p<0.001) among men and women with elevated hsCRP but low to normal cholesterol levels.

Results also showed that for patients in the trial taking rosuvastatin:

-- the combined risk of heart attack, stroke or CV death was reduced by

nearly half (47%, p<0.001).

-- risk of heart attack was cut by more than half (54%, p<0.001).

-- risk of stroke was cut by nearly half (48%, p=0.002).

-- total mortality was significantly reduced by 20% (p=0.02).

These results were accompanied by a median LDL-C reduction of 50% (p<0.001) resulting in an on-treatment median LDL-C of 55 mg/dL.

On the basis of the data, if the results are projected over a period of 5 years, 25 patients would need to be treated to prevent one major cardiovascular event (NNT=25).

The JUPITER results will be presented today at the American Heart Association Scientific Sessions and were simultaneously published online by the New England Journal of Medicine.

"These results provide new information about CRESTOR's effects on CV risk. The JUPITER trial confirmed that CRESTOR dramatically reduces LDL-C cholesterol levels and has now demonstrated a nearly 50% reduction in the risk of heart attack and stroke in a population of patients who had elevated hsCRP but low to normal cholesterol levels," said Howard Hutchinson, Chief Medical Officer for AstraZeneca. "As is appropriate, the medical community, regulators, and guideline committees will now carefully consider these data and any implications for treating patients."

As previously guid
'/>"/>

SOURCE AstraZeneca
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Abbott and AstraZeneca Announce Selection of Next-Generation Fenofibrate ABT-335 and CRESTOR(R) Fixed-Dose Combination
2. New Analysis of METEOR Study Demonstrate Effects of AstraZenecas CRESTOR(R) (Rosuvastatin Calcium) on Atherosclerosis in Patients With Two or More Risk Factors for Cardiovascular Disease
3. Phase III Study of Abbotts Investigational TriLipix(TM) in Combination With AstraZenecas CRESTOR(R) Meets Primary Endpoints on Key Lipids
4. Abbotts Phase III Sub-Group Analysis Shows Investigational TriLipix(TM) in Combination with CRESTOR(R) Improves Key Lipids in Patients with Mixed Dyslipidemia and Type 2 Diabetes
5. Cytokine Demonstrates Oral Efficacy of Small-Molecule MIF Inhibitors
6. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
7. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
8. New Study Presented at WorldSleep 2007 Demonstrates Ramelteon Has Sustained Efficacy Over Six Months in Adults With Chronic Insomnia
9. Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety
10. Lpath Demonstrates Preclinical Efficacy of Lpathomab(TM) and Initiates Humanization Process
11. R7128 Demonstrates Safety and Potent Antiviral Activity in HCV-Infected Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... Calif. , July 28, 2014 ... leader in lifestyle healthcare and subsidiary ... that it has acquired Physician Recommended Nutriceuticals (PRN) ... omega-3s, and related products for dry ... Plymouth Meeting, PA, in a transaction worth up ...
(Date:7/28/2014)...  ResMed (NYSE: RMD ), an innovator ... sleep-disordered breathing and other chronic respiratory conditions, has won ... against Taiwanese medical device manufacturer APEX Medical Corp. (APEX), ... 210 and 220 masks.  The judgment was entered by ... , is appealable, and applies throughout Germany.  ...
(Date:7/28/2014)... CHAPEL HILL, N.C. , July 28, 2014 /PRNewswire/ ... results of a clinical trial demonstrating that CXL-1427, a ... was well tolerated in healthy volunteers. The company has ... failure in a Phase IIa clinical trial designed to ... as its dosing levels. The Phase I ...
Breaking Medicine Technology:ALPHAEON Acquires PRN, A Leading Specialty Nutriceutical Company 2ALPHAEON Acquires PRN, A Leading Specialty Nutriceutical Company 3ResMed Receives Permanent Injunction against APEX in Germany, Continues Enforcement of Patents in Europe 2Cardioxyl Pharmaceuticals Successfully Completes First Clinical Trial For Heart Failure Drug CXL-1427 2
... Delaware, October 10, 2011 As the ... gigabytes of health and health-related technology information, and the ... providers are going to adopt new patterns to successfully ... reimbursement processes. In order to cope with ...
... Pharma, Inc. (Zosano) and Asahi Kasei Pharma Corporation (AKP) ... strategic collaboration for the development, commercialization and supply of ... AKP,s formulation of human parathyroid hormone (human PTH 1-34), ... risk of fracture.  Under the terms ...
Cached Medicine Technology:MedicalBillersandCoders.com Registers a Surge in Outsourcing of Physicians' Billing Requirements 2MedicalBillersandCoders.com Registers a Surge in Outsourcing of Physicians' Billing Requirements 3MedicalBillersandCoders.com Registers a Surge in Outsourcing of Physicians' Billing Requirements 4Zosano Pharma, Inc. and Asahi Kasei Pharma Corporation Enter Exclusive Licensing Agreement for a Weekly Transdermal Patch Formulation of Teribone™ (teriparatide acetate) for Osteoporosis 2Zosano Pharma, Inc. and Asahi Kasei Pharma Corporation Enter Exclusive Licensing Agreement for a Weekly Transdermal Patch Formulation of Teribone™ (teriparatide acetate) for Osteoporosis 3Zosano Pharma, Inc. and Asahi Kasei Pharma Corporation Enter Exclusive Licensing Agreement for a Weekly Transdermal Patch Formulation of Teribone™ (teriparatide acetate) for Osteoporosis 4
(Date:7/29/2014)... Gout was one called “the disease of kings”. However, ... statement essentially moot since many people of today can dine ... are the resources to deal with such a devious disease ... for it, but the effects of the disease are devastating ... , Alternative medicine specialist and author Joe Barton ...
(Date:7/29/2014)... 2014 Consilium Staffing, Your Partner in Locum ... halfway point of 2014, with strong indications the Irving, Texas-based ... of this year. , “This is a great time to ... Consilium Staffing. , “We are proud of what we ... we are even more excited about how things are shaping ...
(Date:7/29/2014)... Guests at Napa Valley's quintessential luxury resort, Auberge ... experience. The top of each luxurious resort bed is adorned ... expertly crafted, 100% Egyptian cotton white duvets and pillow shams ... closer look, words are woven in the linens that serve ... , Intentional breathing and visualization are keys to relaxing ...
(Date:7/29/2014)... 2014 A Forever Recovery , an ... to a great start and gives them a solid foundation ... of the National Cherry Festival kickoff concert held on July ... was co-sponsored by Miller Lite and in partnership with WKLT ... Bay Side Music Stage presented by Blue Cross Blue Shield ...
(Date:7/29/2014)... 2014 Recently, Stwd.co.uk, a distinguished online supplier ... evening dresses . As a summer special offer, all ... to 70 percent off. All new and old customers can ... are proud to announce the new evening outfits. They want ... “We feel happy to launch the big sale. Our cheap ...
Breaking Medicine News(10 mins):Health News:Gout Natural Remedy Report Review | The Ultimate Secret to Eliminating Gout Naturally – Vinamy.com 2Health News:Consilium Staffing Experiences Significant Revenue Growth 2Health News:Auberge Du Soleil Offers INTENTIONS™ by Peacock Alley on Guests' Beds Providing a Unique Sleep Experience 2Health News:A Forever Recovery Sponsors National Cherry Festival Kickoff Concert Featuring Collective Soul on July 5 in Traverse City, MI 2Health News:Cheap Prom Dresses Available At Popular Online Store Stwd.co.uk 2
... June 17 The business of recruiting,university students ... technology industries that rely on this talent pool ... skills. Yet many,companies haven,t changed their university recruiting ... Best Practices, LLC - a leading,pharmaceutical research firm., ...
... linked to disease found in Sub-Saharan Africans , , , TUESDAY, ... a herpes virus and an atypical form of type 2 diabetes ... , Researchers in France, writing in the June 18 issue ... , noted a possible tie between the presence of antibodies for ...
... researcher at the Center for Molecular and Behavioral ... the recent recipient of a "2008 Young Investigator ... to Mental Health Research (previously known as the ... NARSAD is the world,s leading donor-supported organization dedicated ...
... (AMA) announced today the re-election of William A. Hazel, ... consecutive term,on the AMA Board of Trustees., "I ... help physicians achieve,our shared goal of providing the best ... Hazel has been a participant in the AMA House ...
... proper use and possible long-term effects of hydroxyurea in ... influencing doctors to avoid prescribing it to those in ... by specialists at Johns Hopkins. , "We know that ... this drug, which is the only one we have ...
... Pennsylvania School of Medicine found that the activation of ... biology leads to an increase in lung stem cells. ... repair after injury or disease. The investigators published their ... in Nature Genetics . , "The current findings ...
Cached Medicine News:Health News:Best Practices: Achieving Excellence in Staffing and Recruiting Methods 2Health News:Study Ties Herpes Virus to Emerging Form of Diabetes 2Health News:Rutgers scientist receives prestigious 'Young Investigator Award' 2Health News:Effective treatment for sickle cell underused by doctors 2Health News:Penn researchers find key developmental pathway activates lung stem cells 2
Drew Scientific has been making leading edge and top quality CBC systems for over 15 years.,The Excell 16/18 offers a reliable alternative for a 3 part differential....
... therapeutic, expandable turning surface for the BariMaxx™ ... Prevention and treatment of pressure ulcers, Large ... patients using a statuc mattress that would ... whose body weight and size pose a ...
... full-featured healthcare bed system providing a comfortable, ... management of larger patients, ,INDICATIONS: ,Large ... patients at risk for pressure ulcers, ... lbs. (including accessories), ,PRECAUTION: ,Side Rails ...
... beds feature folding head end and foot end deck ... head end and foot end deck panels folded the ... 67". This compact length makes storage, delivery and pick ... is not available on Model 4748B, Basic Maxi Rest ...
Medicine Products: